On Thursday February 7, 2019, KEI submitted comments and intent to testify at the hearing for the 2019 US Trade Representative’s Special 301 review process. This year’s hearing will take place on Wednesday February 27, 2019 at the Office of… Continue Reading
DATE: December 10, 2018 Intent to Testify and Testimony Summary/Comments on Negotiating Objectives for a U.S.-European Union Trade Agreement (USEUTA) Luis Gil Abinader. Knowledge Ecology International 1621 Connecticut Avenue, Northwest, Suite 500, Washington, DC 20009. Phone number +1.202.332.2670. Federal Register… Continue Reading
On 9 November 2018, Brazil delivered the following statement on IP and competition policy at the WTO TRIPS Council under agenda item 13 on Intellectual Property and the Public Interest: Promoting Public Health Through Competition Law and Policy (an item… Continue Reading
KEI has filed a pre-hearing statement for the International Trade Commission, “On the United States-Mexico-Canada Agreement: Likely Impact on the U.S. Economy and on Specific Industry Sectors Investigation (No.TPA-105-003)” KEI-Pre-hearing-statement-ITC-USMCA-30Oct2018 The submission covers the following topoics: Patentable subject matter for… Continue Reading
KEI’s release of TPP Intellectual Property Chapter – May 11, 2015 Draft Link to full text of the IP Chapter: /tpp/11may2015-ip-text 2015:2 KEI TPP Briefing Note: The Evolution of the Article on Patents/Patentable Subject Matter in the Trans-Pacific Partnership Intellectual… Continue Reading
In a 2-1 ruling, the Court of Appeals for the Fourth Circuit has ruled that Maryland’s 2017 price-gouging law (HB 631) is unconstitutional. The law (Md. Code Ann., Health–General §§ 2-801 et seq.) had prohibited price gouging (defined as an… Continue Reading
On March 8, 2018, USTR and the interagency committee on the Special 301 held a hearing. KEI was one of the groups testifying. More on this process here: https://keionline.org/ustr/special301 I began our oral testimony discussing President Trump’s promise, during the… Continue Reading
This is an update to a 2007 report regarding a district court decision in the Innogenetics v. Abbott case here, regarding Abbott’s infringement of Innogenetics’s patents for HCV genotyping. The previous blog discusses the ruling at the district court level… Continue Reading
Bayh-Dole cases involving royalty free or march-in rights 1997 Cellpro case This was a strong case involving two competing medical devices, both invented on NIH grants, and a bad ending. The NIH rejection of the Cellpro march-in request led to… Continue Reading
Read first: Statutory authority for compulsory licenses on patents in the United States KEI Workshop: Feb 24, 2017 – U.S. History, Experiences, and Prospects of Compulsory Licensing of Medical Patents. There is a Video of the event here here. Non-voluntary… Continue Reading